MoonLake Immunotherapeutics Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$263.7MTTM through 30 Jun 2026
Free Cash Flow -$225.2MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-101.2%ROE
-64.2%ROA
Balance Sheet Health
Debt / Equity0.39x
Current Ratio8.60x
Net Debt-$258.9Mnet cash position
Cash & Equivalents$477.9M
Quality Metrics
Altman Z-Score2.79
Piotroski F-Score3 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
Diluted EPS-$3.84TTMFY2025: $-3.53
Dividend
No dividend
Capital Allocation
R&D Spend$221.4M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sonelokimab Development | $0 | View detailsBLA submission for Hidradenitis Suppurativa (HS) planned for late September 2026, with commercial launch targeted for H2 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.